Media - The leading Health & Diagnostic provider for DNA, Genetic Tests & Cancer Screening in Dubai, UAE


Eastern Biotech’s Seminar & Events

Eastern Biotech & Life Sciences have organized a series of seminars in the last three years. The dates of the upcoming seminars in 2010 will be listed on our website soon. These seminars carry Ministry of Health accredited Continuous Medical Education(CME) which are beneficial for the physicians, clinicians and other healthcare workers. Our mission is to create awareness and educate the healthcare practitioners about the new advancements of genetic research and inventions. Please find a glimpse of our CMEs by clicking the following links.

Eastern Biotech Research Director, Dr Sanjida Ahmed, discussed several screening methods which are effective in detection of cervical cancer. In the current biotech world, liquid based cytology (LBC) has an advantage over conventional Pap Smear due to sample stability and sustainability of adequate smears for analysis.

Currently, the overall rate of cervical cancer in women in all GCC States is 3 per 100,000 of the population. Qatar reported the highest with 8.4 per 100,000 women, then Oman (7.8), Bahrain (6.5), UAE (5.9), Kuwait (4.5) and KSA (2.2).
Cervical cancer is caused by a virus called human papillomavirus, or HPV. Dr Sanjida stressed that a person can have HPV for years and not know about it. Most of the time, it clears automatically. If it stays in the body for long, it can lead to cervical cancer years after the person was infected. This is why it is important to have regular Pap tests. A Pap test can find changes in cervical cells before they turn into cancer. If these cell changes are treated, cervical cancer can be prevented.

Eastern Biotech & Life Sciences seminar on “Non Invasive Prenatal Diagnosis of Trisomies and Other Monogenic Disorders” was held in the Novotel Hotel, World Trade Center, Dubai, on the 21st of March 2013. The objective of the seminar is to bring research and best practice to the attention of a wide range of practitioners, especially Gynecologists.

Non-Invasive Prenatal Diagnostic Test is a revolutionary test to UAE to detect Trisomy, a genetic mutation that leads to Down’s syndrome. This new diagnostic test that detects Cell Free Fetal DNA in the maternal blood is set to become the new paradigm in the accurate detection of Down’s syndrome in early pregnancy. The accuracy of the new test in larger studies reaches 99.9% making this new diagnostic modality the most accurate diagnostic test available. Using Next Generation Sequencing ( NGS), which is the state of the art genetic sequencing technology available to date, this genetic test now makes it possible to predict as early as 11 weeks, if the fetus that is in the womb is carrying the genetic mutation that leads to Down’s Syndrome.

Dubai based Al Khaleej ladies club invited Dr. Sanjida Ahmed as the chief guest for an event they organized at the ambassador hotel Bur Dubai on the 28th of September 2011.

Dr. Sanjida spoke on “Genetic testing – what it means to you and your family”, as part of a social awareness segment for women who generally tend to neglect their own health. The talk had also thrown light on the importance of genetic testing for the early detection of Cancer, Down’s syndrome, Thalassemia, and similar conditions which are of major concern. The event gathered a large crowd of women, eager to know more about the benefits of genetic testing. The company brochures were handed out post seminar, to give them more details about the services provided by the company.

Pankaj Sohaney, Marketing Director of Eastern Biotech presented on “Rare Metabolic Disorders Identified in the Newborns of UAE” in the 11th Vietnam-France-Asia- Pacific Conference on Obstetrics & Gynecology in May, 2011. The event was attended by gynecologists and pediatricians from various parts of Aisa and Europe.

In April, UAE hosted the International HUGO Conference for the first time under th patronage of Sheikh Hamdan Al Rasid Al Maktoum, Deputy Ruler of Dubai, UAE Minister of Finance. Eastern Biotech presented the data of their second international publication authored by Dr. Sanjida Ahmed, Director Research and Pankaj Sohaney, Marketing Director at the event. Dr. Sanjida Ahmed was nominated for a poster session in the conference and asked to explain the delegates about her finding presented on “Rare Metabolic Disorders Indentified in the Newborns of UAE“. The event was headed by the president of HUGO, Prof. Edison T. Liu.

Eastern Biotech organized a seminar on ‘Four Decades of Newborn Screening: Technical Advancement & Future Perspective in Management‘ in September, 2010. Each year, at least 4 million babies in the United States are tested for metabolic disorders, and severe disorders are detected in about 5,000 newborns. In the United Arab Emirates (UAE), the national neonatal screening program started by screening for phenylketonuria in January 1995. Screening for congenital hypothyroidism and sickle cell anemia were introduced later by newborn screening program. Unfortunately, NBS is still not mandatory for each child born in UAE. Only the sick babies are being tested for NBS due to a lack of awareness of the benefits and high costs. This is woefully inadequate because most often these disorders appear in babies with no family history of disorders.

Our mission of organizing the seminar was to work closely with local and international community to better understand the specific needs, and to provide products and technologies that meet and exceed the stringent requirements of the crucially important newborn screening tests worldwide.

The speakers from various parts of the world talked about the new development of the screening process and shared their experiences handling the positive cases.

Prominent Speakers
Use of Tendem Mass Spectrometry in Newborn Screening Analysis
Dr. Rohit Cariappa, PhD, DABCC

Approach to Inherited Metabolic Disorders – An Overview
Dr. Monika Kaushal, MD, DM (Neonatologist)

Dr. Fatma Al-Jasmi, Assistant Professor of Paediatrics, Faculty of Medicine and Health Science, UAE University, Al-Ain

Ingredients of Newborn Screening: Myths in Inborn error of Metabolism Management, Disease Profile and Genetic Counselling
Dr. P.K. Rajiv, DCH, MD (Neonatologist)

Need of Comprehensive Newborn Screening Program in UAE
Dr. Sanjida Ahmed, PhD

Department of Biotechnology, Manipal University Dubai Campus
( is proud to organize 5th Annual Biotech Meet-2010

Prominent Speakers
Dr Marco Baccanti PhD
Executive Director
Dubiotech & Research Park

Dr Faruq Badiuddin PhD:
Topic: Genetic Diagnosis – A Tool for Preventive Healthcare
Eastern Biotechnology &
Life Sciences, Dubai

Newborn screening is the process of testing newborn babies for treatable genetic, endocrinological metabolic and hematological diseases. These are also known as inborn errors of metabolism (IEM), disorders which are caused when the body is unable to break down certain naturally produced chemicals, which then accumulate in the body and turn toxic. This toxic build-up can lead to slow physical development or brain damage and, in some cases, even death. Most infants with these disorders show no obvious signs, but the build-up can be rapid enough for the condition to become irreversible within a few days of birth.Newborn screening began in South Carolina in the mid-1960’s with testing for phenylketonuria (PKU) only. Over the years, the test panel has expanded with increased use of tandem mass spectrometry (MS/MS) in newborn screening applications.In the United Arab Emirates (UAE), the national neonatal screening program started by screening for phenylketonuria in January 1995. Since the Implementation of the screening program until Dec 2005, 385,135 infants were screened by MOH with the relative incidence of 1: 1963 for congenital hypothyroidism, 1: 14,812 classic PKU, 0.06% for sickle disease and 0.9% for sickle cell traits. Implementation of National screening program including metabolic screening is under consideration in Bahrain, Kuwait, Oman and other Middle East Countries

Dr. Sanjida Ahmed, Research Director of Eastern Biotech & Life Sciences presented at the Arab Health Congress, January, 2010, one of the world’s largest multi-track medical congress and is by far the best scientific and educational platform for healthcare professionals who wish to remain up-to-date in their area of specialization and earn valuable CME credits.

Dr. Ahmed spoke about the value of Metabolic Disorder Screening in Newborns in the Clinical Chemistry track of MEDLAB Conference. Her presentation was based on the clinical statistics that Eastern Biotech has conducted so far which mentioned that until now 3,000 samples from the mixed population were analyzed from the newborns, the result of the screening show 0.2% of the babies had G6PD deficiency, 0.03% of them had Galactosemia, single Short Chain Hydroxyl Acyle-CoA Dehydrogenase deficiency (SCHAD) and amino acid disorders. She also stated that state- of-the- art technology, Tendem Mass Spectrometry (MS/MS), which has already proved it’s potential to develop expanded newborn screening, has provided Dubai with yet another means to improve the health of it’s citizens and prevent significant morbidity and mortality.

Over 75 doctors from the UAE attended Continuous Medical Education Seminar (CME) organized by Eastern Biotech & Life Sciences on “Cervical Cancer & STIs- Cutting Edge Technologies & Management Strategies”

Dr. Marco Baccant Executive Director of Dubai Biotechnology & Research Park, Dubai, UAE
Dr. Marco Baccant
Executive Director of Dubai Biotechnology & Research Park, Dubai, UAE

Cervical cancer is the second most common cancer among women worldwide, causing 250,000 deaths annually (WHO report). According to a report published by Ministry of Health in 2005, about 43 women die in the UAE alone due to cervical cancer each year. The number has multiplied significantly in the last couple of years. The most recent report suggests, 10 women die each day in the Middle East among the estimated 650 deaths worldwide. HPV (Human Papilloma Virus) is the cause of 99.7% of cervical cancer cases and HPV Genotypes 16 and 18 causes approximately 70% of cervical cancers worldwide. Thus it is important to clearly identify those women at increased risk of developing cervical cancer at an early stage.

The seminar and the workshop were held at Rotana Towers Hotel, Dubai on 1st July 2009, organized by Eastern Biotech & Life Sciences, supported and sponsored by Dubiotech, Glaxo Smithcline & Life Cell International. Ministry of Health, United Arab Emirates acknowledged and rewarded the event with 4.0 CME credit points. Dr. Marco Baccanti, Executive Director of DuBiotech, Dubai presided over the seminar.

The primary objective of the workshop was to raise awareness of cervical cancer among the clinicians and how the latest technologies can be helpful to detect the deadly disease at an early stage, thus prevent the fatalities of such conditions. Speakers suggested that the combination of liquid based cytology used for pap smear with the Digene Hybrid capture 2 techniques for HPV genotyping would be beneficial to detect the infection and the disease at an early stage.

“HPV infection is very common in sexually active men and women. It is usually transient and results only in mild cytological abnormalities. About 80 % of women between 19 and 30 years clear this infection within months or years, but in some cases persistent infection of high risk HPV can lead to the development of cervical cancer” said Dr. Rihab Awad from Mitera Clinic, DHCC, Dubai, during her speech on “The Need of Clinical Education to Raise an Awareness of HPV Screening and Cervical Cancer Prevention”.

Dr. Sanjida Ahmed Research Director for Eastern Biotech & Life Sciences discussed about various subjects such as, Sexually Transmitted Infections (STI), diagnostic tools available to detect them and the cutting edge technologies recently been utilized and marketed by various companies around the world to diagnose these infections. She mentioned that Hybrid Capture 2 DNA Test could be advantageous for the patients in terms of reducing their physical, mental and financial load.

Detecting HPV means better understanding of the risk of cervical cancer was the major focus of Dr. Dinesh Gupta from National Clinical Reference Laboratory, New Delhi India. He spoke on “Opportunistic Screening for Cervical Pre-cancerous Lesions” and informed why the combination screening is vital for prevention and detection of cervical cancer. According to Dr. Gupta, combined screening with liquid based cytology and hybrid capture2 HPV DNA test would identify who’s at risk for high-grade disease and cancer and reduce missed disease caused by false-negative Pap Smear. HPV DNA test is the only FDA approved test to detect 13 high risk HPVs associated with virtually all cervical cancer, he added.

HPV vaccine now available is a new powerful weapon to fight against cervical cancer, Dr. Rima Abu Omar from Al Zahra Hospital, Sharjah, emphasized. She also stated that Vaccine is the Primary Protection against Cervical Cancer and women as young as 9 years should be vaccinated before they approach the puberty.

About Eastern Biotech & Life Sciences:
Eastern Biotech & Life Sciences is a UAE based Biotechnology Company under the Dubai Biotechnology and Research Park, DUBIOTECH, Dubai. The company has a vision to prevent morbidity and mortality among individuals and families with or at risk of genetic, congenital, and/or familial disorders. Eastern Biotech provides quality screening, education and family-centered comprehensive services for people living in the Middle East. The company offers the most recent technologies like Hybrid capture technique combined with Liquid based cytology for detection of HPV and detection of other STIs from a single swab sample.

Eastern Biotech participated in the Meeting about the Forensic Challenges of the 21st Century Conference
Eastern Biotech & Life Sciences exhibited at the “Meeting the Forensic Challenges of the 21st Century Conference” and it was fully sponsored by Dubai Police GHQ, from 19th -23rd April, 2009 at the Dubai Police Officers Club, Dubai. The event inaugurated by Deputy Commandant General of Dubai Police Major General Khamis Al Mazina has 250 organizations participating, including 18 companies, forensic experts, doctors, officers and professors from Arab countries, US, Europe and Australia.

Police are to create a state-of-the-art forensic facility to match the world’s best, the emirate’s chief of police said yesterday. Lt Gen Dahi Khalfan Tamim said that Century Laboratory, now under construction, would use the latest technology and expertise.

Presentation by Eastern Biotech at the PABME Conference
Junaid Faruq, Marketing Director of Eastern Biotech & Life Sciences presented at the conference of Pharmaceuticals and Biotechnology Middle East (PABME), one of the Life Sciences Division events of IIR Middle East, which includes the highly successful Arab Health in its portfolio.

PABME is the largest gathering of Pharma and biotech related specialists in the Middle East – designed to be a global platform for industry leaders to converge, network and develop new business, PABME is the must attend event for any professional within the pharma and biotech industry. Now also with the inclusion of the Pharma section of Arab Health, this is the largest event of its kind in the region.

Junaid Faruq spoke about the “Management of Inherited and Infectious Diseases” in the Current Trends in Pharmaceuticals and Biotechnology session chaired by Dr. Marco Bccanti, Executive Director, Dubai Biotechnology & Research Park (DuBiotech).

Members of Eastern Biotech including Dr. Faruq M Badiuddin, Dr. Sanjida Ahmed and Pankaj Sohaney were present in the occasion

Syndrome Based Diagnostics: A Single Test using DNA Macrochip to Detect Multiple Pathogens in Eye & Brain Infection

Dr. Ravi Kumar, MBBS, PhD (NeuroChemistry)

  • Chairman and Managing Director, XCyton Diagnostics Limited, India.
  • General Secretary, Association of Biotech Led Enterprises, India

Venue: NMC Specialty Hospital – Dubai, UAE

Risk Reduction of Genetic Disorders by Premarital, Prenatal & Neonatal Screening

Dr. Sanjida Ahmed

  • PhD, Cell Biology
  • Director, Research, Eastern Biotech & Life Sciences, Dubai, UAE

Venue: Oasis Hospital, Al Ain, UAE

Recent Advances in Genetic Testing
Genetic Testing has now reached a stage where it is becoming increasingly applicable for rapid and accurate diagnosis of common infective / congenital disorders as well as the basis for prediction of cancers and lifestyle diseases.

These advances are opening up new avenues for the clinicians to offer their patients innovative tools to achieve optimum health. ‘Advanced Genetic Testing in the prediction & diagnosis of disease’ conference is aiming to introduce a broad spectrum of new diagnostic tools available to clinicians in an attempt to incorporate there use in routine practices.

The conference is proudly organized by Eastern Biotech & Life Sciences; a Genetic Biotechnological company based out of DuBiotech, Dubai and will be held in Dubai (UAE) on the 27th of November 2008. It is supported by the Ministry of Health, United Arab Emirates and has been formally granted 3.0 CME credit points.

The conference aims to promote knowledge exchange on using diagnostic testing as a tool for supporting the advancement of genetic innovation throughout the world. The conference will bring together approximately 75 key industry figureheads and stakeholders throughout the GCC headlined by 4 internationally acclaimed genetic specialists presenting their knowledge and ideas fostering genetic and biotechnological innovation specifically:


  • Genetic Disorders in Arab Populations
  • Syndrome Based Diagnostics: A Single Test using DNA Macrochip to Detect Multiple Pathogens in Eye and Brain
  • Birth Defects and Congenital Abnormalities in UAE: Risk Reduction by Counseling and Genetic Testing Using Molecular and Cytogenetic Techniques
  • New DNA Based Diagnostic Tests for Prediction of Diabetes, Heart Disease, Breast and Prostate CancerAs a part of the event Eastern Biotech & Life Sciences will conduct its inaugural network meeting including product development and contribution program aiming to enhance the education and management of genetic diagnostic testing tools within the GCC.